Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Leukemia
69%
Cyclophosphamide
52%
Neoplasm
51%
Pharmacokinetics
43%
Breast Cancer
34%
Chemotherapy
33%
Clinical Trial
28%
Disease
27%
Pharmacodynamics
27%
Phase I Trials
25%
Irinotecan
24%
Acute Myeloid Leukemia
23%
Progression Free Survival
22%
Cisplatin
22%
Acute Lymphoblastic Leukemia
20%
Hyperthermia
20%
Overall Survival
19%
Graft Versus Host Reaction
18%
Topotecan
17%
High Dose Chemotherapy
17%
Pharmacogenetics
16%
Acute Graft Versus Host Disease
15%
Clinical Trial Design
15%
Adverse Event
14%
Gemcitabine
14%
Paclitaxel
14%
Solid Malignant Neoplasm
13%
Neutropenia
13%
Anticarcinogen
12%
Fluorouracil
11%
Carmustine
11%
Cytarabine
10%
Prostate Cancer
10%
Prospective Study
10%
Sarcoma
10%
Remission
9%
Drug Development
9%
Phase II Trials
9%
Randomized Clinical Trial
9%
Biological Marker
9%
Immunotherapy
9%
Methotrexate
8%
Granulocyte Macrophage Colony Stimulating Factor
8%
Doxorubicin
8%
Maximum Tolerated Dose
8%
Acute Leukemia
8%
Hematologic Malignancy
8%
Fludarabine
7%
Placebo
7%
Keyphrases
Leukemia
48%
Post-transplantation Cyclophosphamide (PTCy)
29%
Graft-versus-host Disease (GvHD)
23%
Acute Myeloid Leukemia
21%
Phase I Study
21%
High Dose
19%
Confidence Interval
17%
Haploidentical Transplantation
17%
Allogeneic Bone Marrow Transplantation
16%
Irinotecan
16%
Cisplatin
15%
Chemotherapy
15%
Pharmacogenetics
15%
Pharmacokinetics
15%
HLA-haploidentical
14%
High-dose Chemotherapy
14%
Acute Lymphoblastic Leukemia
14%
Topotecan
14%
Overall Survival
13%
Phase I Trial
13%
Progression-free Survival
13%
Nonmyeloablative
12%
Tumor
11%
Neutropenia
11%
Patients with Cancer
11%
Hepatic Dysfunction
10%
Randomised Discontinuation Trial
10%
Clinical Trials
10%
Dose-limiting Toxicity
9%
High Risk
9%
Phase II Study
9%
HLA Matching
8%
Adult Patients
8%
Systemic Therapy
8%
Etoposide
8%
Bayesian Decision Analysis
8%
Older Adults
8%
Cyclophosphamide
8%
Cancer Patients
8%
Granulocyte Colony-stimulating Factor (G-CSF)
8%
Myelodysplastic Syndrome
8%
Utility Function
8%
Pharmacodynamics
8%
Clinical Pharmacology
8%
Maximum Tolerated Dose
7%
Event-free Survival
7%
Bone Marrow Mononuclear Cells
7%
Oncology
7%
Chronic Myeloid Leukemia
7%
Probability Model
7%
Medicine and Dentistry
Neoplasm
42%
Breast Cancer
28%
Acute Lymphoblastic Leukemia
22%
Leukemia
21%
Cyclophosphamide
21%
Acute Myeloid Leukemia
17%
Malignant Neoplasm
17%
High Dose Chemotherapy
17%
Arm
16%
Drug Megadose
16%
Progression Free Survival
15%
Overall Survival
15%
Disease
14%
Tumor Blood Flow
11%
Pharmacogenetics
11%
Clinical Trial
11%
Oncology
10%
Radiation Therapy
9%
Immunotherapy
9%
Minimal Residual Disease
9%
T Cell
9%
Non Small Cell Lung Cancer
8%
Bone Marrow Transplantation
8%
Arteriole
8%
External Beam Radiotherapy
7%
Phase I Trials
7%
Leukocyte
7%
Continuous Infusion
7%
Tyrosine-Kinase Inhibitor
7%
Vorinostat
7%
Oxygen
7%
Cancer Screening
7%
Granulocyte Macrophage Colony Stimulating Factor
7%
Autologous Bone Marrow Transplantation
7%
Prostate Cancer
7%
Paclitaxel
7%
Phase II Trials
7%
Topotecan
7%
Prospective Study
7%
Decitabine
7%
Precursor
7%
Adjuvant Chemotherapy
7%
Cytarabine
7%
Soft Tissue Sarcoma
7%
Colorectal Cancer
7%
Carboplatin
7%
Graft Versus Host Reaction
6%
Targeted Therapy
6%
Systemic Therapy
6%
Nivolumab
5%